Betaville

Hikma Pharmaceuticals eyes $1 billion purchase of CorePharma

I realise most of the dealmaking community is currently focused on the risk that some large pharmaceutical deals may collapse. But I have stumbled across a potential pharmaceutical deal that is unlikely to be affected by the US government's attempt to clamp down on corporate "tax inversions"...